Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Lisata Therapeutics Inc. (LSTA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: LSTA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $16.67
1 Year Target Price $16.67
| 1 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -29.85% | Avg. Invested days 25 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 24.07M USD | Price to earnings Ratio - | 1Y Target Price 16.67 |
Price to earnings Ratio - | 1Y Target Price 16.67 | ||
Volume (30-day avg) 3 | Beta 1 | 52 Weeks Range 1.87 - 4.20 | Updated Date 06/29/2025 |
52 Weeks Range 1.87 - 4.20 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.3 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2165.5% |
Management Effectiveness
Return on Assets (TTM) -35.05% | Return on Equity (TTM) -56.92% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -1666029 | Price to Sales(TTM) 24.07 |
Enterprise Value -1666029 | Price to Sales(TTM) 24.07 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.82 | Shares Outstanding 8598200 | Shares Floating 7101945 |
Shares Outstanding 8598200 | Shares Floating 7101945 | ||
Percent Insiders 20.18 | Percent Institutions 9.11 |
Analyst Ratings
Rating 2 | Target Price 16.67 | Buy 2 | Strong Buy 1 |
Buy 2 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Lisata Therapeutics Inc.
Company Overview
History and Background
Lisata Therapeutics, Inc., formerly Caladrius Biosciences, Inc., is a clinical-stage pharmaceutical company. It was renamed Lisata Therapeutics in 2022. The company focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors.
Core Business Areas
- Drug Development: Focuses on developing and commercializing drug candidates targeting solid tumors. Their primary focus is on their investigational drug, LSTA1.
Leadership and Structure
The leadership team includes David J. Mazzo, PhD, as CEO. The organizational structure comprises research and development, clinical operations, and administrative functions.
Top Products and Market Share
Key Offerings
- LSTA1: LSTA1 is Lisata Therapeutics' lead product candidate, designed to activate a novel uptake pathway for anti-cancer therapies in solid tumors. It is currently in clinical development. Market share data isn't applicable at this stage as the drug is not yet approved. Competitors would be other companies developing cancer therapies and targeted drug delivery systems.
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically the oncology segment, is characterized by high growth, intense competition, and significant investment in research and development.
Positioning
Lisata Therapeutics is positioning itself as a player in targeted drug delivery for solid tumors. Its competitive advantage lies in the novel uptake pathway activated by LSTA1.
Total Addressable Market (TAM)
The TAM for cancer therapeutics is substantial, estimated in the hundreds of billions of dollars. Lisata's specific TAM depends on the success of LSTA1 and the specific cancer indications it targets. It currently occupies a small part of it but seeks to increase the part.
Upturn SWOT Analysis
Strengths
- Novel targeted drug delivery technology
- Experienced management team
- Proprietary technology platform
Weaknesses
- Single lead product candidate
- Limited financial resources
- High regulatory risk
Opportunities
- Successful clinical trials
- Partnerships with larger pharmaceutical companies
- Expansion into new cancer indications
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- MRNA
- LLY
- NVO
Competitive Landscape
Lisata faces strong competition from established pharmaceutical companies. Its advantage lies in its targeted drug delivery technology, but it needs to demonstrate clinical efficacy to gain market share. It is a much smaller company and the market share is for context only.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily driven by clinical trial progress and financing activities.
Future Projections: Future growth depends on the success of LSTA1 and potential partnerships. Analyst estimates are available from financial data providers.
Recent Initiatives: Recent strategic initiatives include advancing LSTA1 through clinical trials and securing funding for research and development.
Summary
Lisata Therapeutics is a clinical-stage biotech company with a focus on targeted drug delivery for solid tumors, particularly through its lead candidate, LSTA1. Its success depends on positive clinical trial results and strategic partnerships, while it faces challenges in securing funding and competing with established pharmaceutical giants. The absence of dividend payouts and shareholder return programs reflects its developmental stage. Strong growth is contingent upon successful development and commercialization of LSTA1, and they must be mindful of the intense competitive landscape.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC filings
- Company website
- Financial news sources
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lisata Therapeutics Inc.
Exchange NASDAQ | Headquaters Basking Ridge, NJ, United States | ||
IPO Launch date 1999-03-01 | President, CEO & Director Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 26 | Website https://www.lisata.com |
Full time employees 26 | Website https://www.lisata.com | ||
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with a range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.